Royalty Pharma plc Provision for Loan and Lease Losses
Royalty Pharma plc (RPRX) reported Provision for Loan and Lease Losses of $184.62 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Notes
us-gaap:ProvisionForLoanAndLeaseLosses · last filed 2022-05-05
- Royalty Pharma plc provision for loan and lease losses for the quarter ending 2022-03-31 was $184.62M, a 36.83% decline year-over-year.
- Royalty Pharma plc provision for loan and lease losses for the quarter ending 2021-12-31 was $266.50M, a 106.05% increase year-over-year.
- Royalty Pharma plc provision for loan and lease losses for the quarter ending 2021-09-30 was $137.84M.
- Royalty Pharma plc provision for loan and lease losses for the quarter ending 2021-06-30 was -$243.76M, a 615.59% decline year-over-year.
- Royalty Pharma plc provision for loan and lease losses for fiscal 2021 was $452.84M, a 96.17% increase from fiscal 2020.
- Royalty Pharma plc provision for loan and lease losses for fiscal 2020 was $230.84M.
- Royalty Pharma plc provision for loan and lease losses for fiscal 2019 was -$1.02B.
- Royalty Pharma plc provision for loan and lease losses for fiscal 2018 was -$57.33M.
| Period end | Provision for Loan and Lease Losses 3 month | Provision for Loan and Lease Losses 6 month | Provision for Loan and Lease Losses 9 month | Provision for Loan and Lease Losses 12 month |
|---|---|---|---|---|
| 2022-03-31 | $184.62M 10-Q · filed 2022-05-05 | $451.13M derived: sum of 2 quarters · filed 2022-05-05 | $588.96M derived: sum of 3 quarters · filed 2022-05-05 | $345.20M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $266.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $404.34M derived: sum of 2 quarters · filed 2022-02-15 | $160.58M derived: sum of 3 quarters · filed 2022-02-15 | $452.84M 10-K · filed 2022-02-15 |
| 2021-09-30 | $137.84M 10-Q · filed 2021-11-10 | -$105.92M derived: sum of 2 quarters · filed 2021-11-10 | $186.34M 10-Q · filed 2021-11-10 | $315.68M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-06-30 | -$243.76M 10-Q · filed 2021-08-11 | $48.50M 10-Q · filed 2021-08-11 | $177.84M derived: sum of 3 quarters · filed 2022-05-05 | $144.05M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | $292.26M 10-Q · filed 2022-05-05 | $421.60M derived: sum of 2 quarters · filed 2022-05-05 | $387.81M derived: sum of 3 quarters · filed 2022-05-05 | $435.09M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $129.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $95.55M derived: sum of 2 quarters · filed 2022-02-15 | $142.83M derived: sum of 3 quarters · filed 2022-02-15 | $230.84M 10-K · filed 2022-02-15 |
| 2020-09-30 | -$33.79M 10-Q · filed 2021-11-10 | $13.49M derived: sum of 2 quarters · filed 2021-11-10 | $101.50M 10-Q · filed 2021-11-10 | -$817.66M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $47.28M 10-Q · filed 2021-08-11 | $135.29M 10-Q · filed 2021-08-11 | -$783.87M derived: sum of 3 quarters · filed 2022-02-15 | -$906.21M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $88.01M 10-Q · filed 2021-05-11 | -$831.15M derived: sum of 2 quarters · filed 2022-02-15 | -$953.49M derived: sum of 3 quarters · filed 2022-02-15 | -$881.28M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$919.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$1.04B derived: sum of 2 quarters · filed 2022-02-15 | -$969.29M derived: sum of 3 quarters · filed 2022-02-15 | -$1.02B 10-K · filed 2022-02-15 |
| 2019-09-30 | -$122.34M 10-Q · filed 2020-11-12 | -$50.13M derived: sum of 2 quarters · filed 2020-11-12 | -$100.16M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $72.21M 10-Q · filed 2020-08-12 | $22.18M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | -$57.33M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |